In the latest session, Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) closed at $5.79 up 1.40% from its previous closing price of $5.71. In other words, the price has increased by $+0.08 from its previous closing price. On the day, 4004748 shares were traded.
Ratios:
For a deeper understanding of Biocryst Pharmaceuticals Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.21 and its Current Ratio is at 5.54.
On September 18, 2023, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $9 to $10.
Jefferies Upgraded its Hold to Buy on August 04, 2023, while the target price for the stock was maintained at $11.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 15 when SANDERS MACHELLE sold 4,000 shares for $7.98 per share. The transaction valued at 31,920 led to the insider holds 25,611 shares of the business.
Hutson Nancy J sold 12,866 shares of BCRX for $103,443 on Jun 14. The Director now owns 81,818 shares after completing the transaction at $8.04 per share. On Apr 03, another insider, Thackray Helen M., who serves as the Chief R&D Officer of the company, sold 7,000 shares for $8.29 each. As a result, the insider received 58,030 and left with 207,275 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1.19B and an Enterprise Value of 1.64B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.58. Its current Enterprise Value per Revenue stands at 5.16 whereas that against EBITDA is -13.35.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.92, which has changed by -35.48% over the last 52 weeks, in comparison to a change of 28.18% over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $9.33, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 5.89, while the 200-Day Moving Average is calculated to be 6.65.
Shares Statistics:
For the past three months, BCRX has traded an average of 3.92M shares per day and 3.29M over the past ten days. A total of 205.77M shares are outstanding, with a floating share count of 197.21M. Insiders hold about 3.71% of the company’s shares, while institutions hold 85.16% stake in the company. Shares short for BCRX as of Jan 31, 2024 were 29.04M with a Short Ratio of 7.42, compared to 30.08M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 14.18% and a Short% of Float of 15.78%.
Earnings Estimates
There are 11 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.38, while EPS last year was -$0.38. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.15 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.87 and -$1.26 for the fiscal current year, implying an average EPS of -$1.06. EPS for the following year is -$0.72, with 12 analysts recommending between -$0.22 and -$1.41.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $90.01M this quarter.It ranges from a high estimate of $93.5M to a low estimate of $86M. As of the current estimate, Biocryst Pharmaceuticals Inc.’s year-ago sales were $79.55M, an estimated increase of 13.20% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $87.65M, an increase of 27.40% over than the figure of $13.20% in the same quarter last year. There is a high estimate of $89M for the next quarter, whereas the lowest estimate is $86.81M.
A total of 11 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $331.5M, while the lowest revenue estimate was $324M, resulting in an average revenue estimate of $327.81M. In the same quarter a year ago, actual revenue was $270.83M, up 21.00% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $393.73M in the next fiscal year. The high estimate is $428.96M and the low estimate is $326M. The average revenue growth estimate for next year is up 20.10% from the average revenue estimate for this year.
